Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model

Area of Science:

• Nephrology
• Molecular Biology
• Pharmacology

Background:

• Autosomal dominant polycystic kidney disease (ADPKD) is a primary cause of end-stage renal disease (ESRD).
• Elevated cyclic AMP (cAMP) levels are a key factor in ADPKD pathogenesis.
• Compounds targeting adenylyl cyclase 6 (AC6) activity, like tolvaptan and pasireotide, show promise in slowing cyst growth.

Purpose of the Study:

• To evaluate the efficacy of tolvaptan and pasireotide, individually and in combination, for treating ADPKD.
• To investigate the role of AC6 and cAMP in ADPKD progression using a preclinical model.

Main Methods:

• A hypomorphic Pkd1(R3277C/R3277C) (Pkd1(RC/RC)) mouse model was utilized in a 5-month preclinical trial.
• The model was backcrossed to the C57BL/6 background to minimize disease variability.
• The effect of AC6 stimulation was confirmed using desmopressin.

Main Results:

• Both tolvaptan and pasireotide significantly reduced cyst progression when administered alone.
• Combination therapy demonstrated a clear additive effect, further slowing cyst development.
• Combined treatment markedly decreased cystic and fibrotic volume and normalized cAMP levels to wild-type.
• Pasireotide also corrected hepatic hypertrophy observed in the Pkd1(RC/RC) mice.

Conclusions:

• The additive effect of tolvaptan and pasireotide underscores the critical role of AC6 and cAMP in ADPKD.
• Combination therapy represents a promising strategy for managing ADPKD progression in patients.